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Benefits of switching from a conventional to a low-GDP
bicarbonate/lactate-buffered dialysis solution in a rat model
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Benefits of switching from a conventional to a low-glucose
degradation product (GDP) bicarbonate/lactate-buffered dial-
ysis solution in a rat model.
Background. Long-term exposure to standard peritoneal
dialysis fluid (PDF) results in alterations in peritoneal mor-
phology and function. Studies investigating the long-term ef-
fects on the peritoneum of a low-glucose degradation product
(GDP) bicarbonate/lactate-buffered PDF demonstrated its su-
perior biocompatibility. We examined the potential of the low-
GDP bicarbonate/lactate-buffered solution to reverse or reduce
standard PDF-induced peritoneal alterations.
Methods. Female Wistar rats received twice daily intraperi-
toneal infusions with either a lactate-buffered solution with
3.86% glucose at pH 5.5 (Dianeal, referred to as standard
PDF), or a low-GDP bicarbonate/lactate-buffered solution with
3.86% glucose at physiologic pH (Physioneal, referred to as
bicarbonate/lactate PDF) for different periods of time: (1) 12
weeks Dianeal (N = 9); (2) 12 weeks Physioneal (N = 9); (3)
20 weeks Dianeal (N = 11); (4) 20 weeks Physioneal (N =
10); (5) 12 weeks Dianeal followed by 8 weeks Physioneal
(N = 10).
Results. Chronic standard PDF exposure resulted in loss of ul-
trafiltration capacity, increased VEGF expression and vascular
density, higher advanced glycation end product (AGE) accumu-
lation, up-regulation of TGF-b expression, and development
of fibrosis compared to low-GDP bicarbonate/lactate-
buffered PDF. The PDF-induced alterations were
time-dependent. Crossover from standard PDF to low-GDP bi-
carbonate/lactate PDF resulted in a less impaired ultrafiltration
(UF), less pronounced VEGF expression and neoangiogenesis,
and less severe AGE accumulation, TGF-b expression, and
fibrosis compared to continuous standard PDF exposure for
20 weeks.
Conclusion. Low-GDP bicarbonate/lactate-buffered PDF
has the potential to slow down standard PDF-induced peri-
toneal membrane damage.
Loss of ultrafiltration capacity is an important cause
of treatment failure in peritoneal dialysis (PD), requiring
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the transfer of patients to hemodialysis or the introduc-
tion of an episode of peritoneal rest. Long-term treatment
of PD patients with conventional peritoneal dialysis fluid
(PDF) is associated with fibrosis and neoangiogenesis,
which is especially pronounced in patients with ultrafil-
tration (UF) failure [1–3].
In vitro studies demonstrated that low-glucose degra-
dation product (GDP), bicarbonate/lactate-buffered
PDF better preserved viability and functions of peri-
toneal leukocytes, mesothelial cells, and fibroblasts than
conventional solutions [4–6]. In experimental animal
models, the low-GDP bicarbonate/lactate-buffered PDF
was associated with less functional and structural alter-
ations of the peritoneal membrane than standard PDF [7,
8]. In clinical trials, alleviation of infusion pain, improved
ultrafiltration, increases in CA125 concentrations, and a
decrease in hyaluronan levels were observed [9, 10].
While several lines of evidence indicate that these new
PDF have the potential to induce less peritoneal mem-
brane damage than standard PDF, their ability to reverse
or reduce standard PDF-associated structural and func-
tional alterations of the peritoneum has not been ex-
amined. If true, a switch to a more biocompatible PDF
could be an alternative to peritoneal resting or transfer
to hemodialysis in patients with peritoneal membrane
dysfunction. We therefore studied in a standardized rat
model of chronic PDF exposure the potential reversibil-
ity of standard PDF-induced alterations during treatment
with a low-GDP bicarbonate/lactate-buffered PDF.
METHODS
Laboratory animals
The studies were performed in 49 female Wistar rats
(Iffacredo, Brussels, Belgium) with a mean body weight
of 214 ± 1 g, receiving care in accordance with the
national guidelines for care and use of laboratory an-
imals. A subcutaneous port (PMINA-CBAS-C30 Solo-
port; Instech Solomon, Plymouth Meeting, PA, USA)
was implanted in the neck under halothane (Fluothane;
Zeneca, Destelbergen, Belgium) anesthesia in sterile
conditions. The attached polyurethane, heparin-coated
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catheter (Instech Solomon) was tunnelled over the left
flank to the peritoneal cavity [11]. After surgery, the an-
imals received an intramuscular injection of buprenor-
phine (0.1 mL/kg Temgesic; Schering Plough NV/SA,
Brussels, Belgium). The first week after implantation,
catheters were flushed once daily with 1 mL of Earle’s
balanced salt solution (EBSS; ICN Biomedicals, Inc.,
Aurora, OH, USA). Thereafter, 10 mL of PDF was ad-
ministered twice daily during 12 or 20 weeks. Oxacilline
(2.5 mg/day Penstapho; Bristol-Myers Squibb, Brussels,
Belgium) and gentamycine (0.04 mg/day Geomycine;
Shering-Plough) were added to all solutions [12]. Labo-
ratory technicians wore masks and gloves during manipu-
lations. The area of the port was disinfected with ethanol
97% 20 seconds before puncture.
Study protocol
Five groups of animals were exposed to either a
lactate-buffered solution with 3.86% glucose at pH 5.5
(Dianeal; Baxter, SA, Lessines, Belgium), referred to
as standard PDF, or to a low-GDP bicarbonate/lactate-
buffered solution with 3.86% glucose at physiologic pH
(Physioneal; Baxter), referred to as bicarbonate/lactate
PDF, for different periods of time: (1) 12 weeks stan-
dard PDF (N = 9); (2) 12 weeks bicarbonate/lactate PDF
(N = 9); (3) 20 weeks standard PDF (N = 11); (4) 20
weeks bicarbonate/lactate PDF (N = 10); (5) 12 weeks
standard PDF followed by 8 weeks bicarbonate/lactate
PDF (N = 10). The weight of the rats was recorded
weekly. Catheter patency and the integrity of the skin
of the abdomen and around the port were evaluated
twice daily. In case of catheter obstruction, an attempt
was made to infuse fluids under halothane anesthesia.
In case of persistent catheter obstruction, skin lesions,
or severe weight loss, dialysate and catheter tip cultures,
as well as dialysate white blood cell (WBC) counts were
obtained, and the animal was sacrificed. At 4-week inter-
vals, dialysate cultures and WBC counts were performed
on 2 mL of fluid obtained through a sterile abdominal
puncture with a silicon catheter (Venflon; Becton Dick-
inson, Erembodegem-Aalst, Belgium) under halothane
anesthesia 4 hours after the last dialysate injection. WBC
counts were performed in a Bu¨rker chamber. Infection
was arbitrarily defined as a positive dialysate culture with
a dialysate WBC count higher than 1000/mm3 [11, 12].
Study of peritoneal function
After the predefined period of dialysate exposure,
rats were anaesthetized with thiobutabarbital (100 mg/kg
s.c. Inactin; RBI, Natick, MA, USA). The trachea was
intubated, and a jugular vein was cannulated for contin-
uous infusion of isotonic saline. After 30 minutes, a sili-
cone catheter was inserted in the abdomen, and 15 mL of
3.86% Dianeal was infused. After 120 minutes, dialysate
was recovered through the silicone catheter, and samples
were obtained for culture and WBC counts. The abdomen
was opened by midline incision to collect the rest of the
dialysate for determination of net UF, and to sample tis-
sue. The tunnelled polyurethane catheter was removed
in a sterile way, and the tip was cultured.
Study of peritoneal morphology
One sample of visceral and parietal peritoneum was ob-
tained in each experimental animal, fixed in 4% neutral
buffered formalin, and embedded in paraffin. Five lm
sections were cut for histology and immunohistochem-
istry.
Immunostaining for endothelial NO synthase (eNOS),
vascular endothelial growth factor (VEGF), transform-
ing growth factor-b (TGF-b), and advanced glycation end
products (AGE) were performed. Sections were deparaf-
finized, rehydrated, incubated in 3% H2O2 in phosphate-
buffered saline (PBS) for 15 minutes to block endoge-
nous peroxidase, and washed in 10% normal horse serum
(Sigma, St. Louis, MO, USA) in PBS for 20 minutes
to block nonspecific binding. Subsequently, they were
incubated with the primary antibody, mouse antihu-
man eNOS (Transduction Laboratories, Lexington, KY,
USA), mouse antihuman VEGF (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), rabbit antihuman TGF-b1
(Santa Cruz Biotechnology), and mouse antihuman AGE
(6D12; Cosmo Bio, Ltd., Tokyo, Japan), respectively.
Thereafter, a biotinylated IgG (Vector Laboratories,
Burlingame, CA, USA) and streptavidine-peroxidase
were applied for 45 minutes each. 3,3′diaminobenzidine
(DAB) was used as the chromogenic substrate to visual-
ize immunolabelling, resulting in a brown precipitate.
The degree of fibrosis was evaluated using a Picro
Sirius Red staining F3B (Klinipath, Geel, Belgium). Sec-
tions were deparaffinized, rehydrated, and stained briefly
with Giemsa. Subsequently, sections were washed and
stained with the Sirius Red solution, resulting in a brick
red staining of all fibrillary collagen.
Morphometric analysis
Morphometric measurements of the eNOS, VEGF,
TGF-b , AGE, and Picro Sirius Red staining were made
by a blinded operator with a Zeiss Axiophot microscope
(Zeiss, Oberkochen, Germany) at magnification ×200.
For each sample of peritoneum, 2 sections were analyzed
quantitatively with a computerized image analysis sys-
tem (Zeiss). A camera sampled the image of the stained
sections, and generated an electronic signal proportional
to the intensity of illumination, which was then digitized
into picture elements or pixels. The digital representation
of the tissue was analyzed with KS400 Software (Zeiss).
Each pixel in a color image was divided into 3 color com-
ponents (hue, saturation, and intensity). The threshold
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Fig. 1. Net ultrafiltration after a 120-minute
dwell of 15 mL of 3.86% glucose dialysate
in experimental animals exposed to stan-
dard lactate-buffered peritoneal dialysis fluid
(PDF) for 12 or 20 weeks (N = 9 or N = 11,
closed bars), low-glucose degradation prod-
uct (GDP) bicarbonate/lactate-buffered PDF
(N = 9 or N = 10, open bars) for 12 or 20
weeks, and standard lactate-buffered PDF for
12 weeks followed by exposure to low-GDP
bicarbonate/lactate-buffered PDF for 8 weeks
(N = 10, hatched bar). ∗P < 0.01 vs. Dianeal
(20 weeks).
for each color component of the staining was defined and
kept constant throughout the analysis. In a predefined
area, eNOS, VEGF, TGF-b , AGE, and Picro Sirius Red
staining were measured and expressed as a percentage.
In addition, eNOS-labeled blood vessels were counted as
N/field.
Statistical analyses
The results are expressed as mean ± SEM. Statisti-
cal analysis was performed using analysis of variance
(ANOVA) and, where appropiate, the Tukey test was
used as multiple comparison t test. The significance level
was set at P ≤ 0.05.
RESULTS
Technique survival and infection rate of laboratory
animals
Body weight was similar in the different experimen-
tal groups at all time points (data not shown). Technique
survival was 100% in all groups. Except for one transient
episode of infection, defined as a positive dialysate cul-
ture and a dialysate WBC count >1000/mm3, in an animal
exposed to the standard PDF, no infection was diagnosed
(data not shown).
Ultrafiltration
After 12 weeks of PDF exposure, net UF did not differ
significantly between animals exposed to standard PDF
and to bicarbonate/lactate PDF, although a trend toward
a better UF in the bicarbonate/lactate PDF group was
present (Fig. 1). At 20 weeks, net UF was significantly
lower in the animals exposed to standard PDF than in the
crossover group and in bicarbonate/lactate PDF-treated
group. Net UF was not different between the crossover
and the bicarbonate/lactate PDF group (Fig. 1).
Peritoneal morphology
Vascular density was higher in the standard PDF than
in the bicarbonate/lactate PDF group, both after 12 weeks
and 20 weeks of PDF exposure (Table 1, Fig. 2). In
the crossover group, vascular density was lower than in
the standard PDF group, and did not differ significantly
from that of the bicarbonate/lactate PDF group (Table 1,
Fig. 2). After 12 weeks of PDF exposure, eNOS expres-
sion was not different in the standard PDF and bicar-
bonate/lactate PDF group (Table 1, Fig. 2). At 20 weeks,
eNOS was up-regulated in the standard PDF group com-
pared with the bicarbonate/lactate PDF group. Inter-
mediary values were measured in the crossover group
(Table 1, Fig. 2). VEGF expression was more pronounced
in animals exposed to standard PDF compared to those
exposed to bicarbonate/lactate PDF, both at 12 and 20
weeks (Table 1, Fig. 3). At 20 weeks, VEGF expression in
the crossover group did not differ significantly from that
in other experimental groups (Table 1, Fig. 3). Vascular
density correlated positively with both eNOS (Pearson
r = 0.6646, P < 0.0001) and VEGF expression (Pearson
r = 0.6004, P < 0.0001).
AGE accumulation was more pronounced in the stan-
dard PDF group than in the other experimental groups at
12 and 20 weeks (Table 1, Fig. 4). No difference in AGE
accumulation was found between the crossover group
and the bicarbonate/lactate PDF-treated group (Table 1,
Fig. 4). After 12 weeks of PDF exposure, TGF-b expres-
sion was not different in the standard PDF and bicar-
bonate/lactate PDF group (Table 1, Fig. 5). At 20 weeks,
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Table 1. Histologic and immunohistochemical analysis of the peritoneum
Dianeal Physioneal Dianeal Physioneal
12 weeks 12 weeks 20 weeks Crossover 20 weeks
Blood vessels N/mm2 183.93 ± 16.84 120.75 ± 6.34a 299.72 ± 9.10 255.46 ± 16.06b 219.53 ± 11.70b
eNOS staining% 0.36 ± 0.05 0.36 ± 0.06 0.88 ± 0.10 0.58 ± 0.04c,d 0.39 ± 0.05c
VEGF staining% 1.04 ± 0.12 0.62 ± 0.09e 1.40 ± 0.12 1.13 ± 0.09 0.89 ± 0.10f
Picro Sirius Red staining% 2.46 ± 0.28 1.80 ± 0.14e 3.76 ± 0.28 3.24 ± 0.16 2.95 ± 0.21b
AGE staining% 3.41 ± 0.88 1.06 ± 0.12e 3.88 ± 0.21 1.22 ± 0.28g 1.41 ± 0.19g
TGF-b staining% 0.47 ± 0.04 0.58 ± 0.13 1.55 ± 0.30 1.23 ± 0.14d 0.77 ± 0.15b
aP < 0.005 vs. Dianeal (12 weeks); bP < 0.05 vs. Dianeal (20 weeks); cP < 0.01 vs. Dianeal (20 weeks); dP < 0.05 vs. Physioneal (20 weeks); eP < 0.05 vs. Dianeal (12
weeks); fP < 0.005 vs. Dianeal (20 weeks); gP < 0.0001 vs. Dianeal (20 weeks).
Fig. 2. Immunostaining for eNOS of the visceral peritoneum (×200) exposed to standard lactate-buffered PDF for 20 weeks (A, N = 11), standard
lactate-buffered PDF for 12 weeks followed by exposure to low-GDP bicarbonate/lactate-buffered PDF for 8 weeks (B, N = 10), and low-GDP
bicarbonate/lactate-buffered PDF for 20 weeks (C, N = 10).
Fig. 3. Vascular endothelial growth factor (VEGF) expression, expressed as percentage staining, was evaluated by a VEGF immunostaining of the
visceral peritoneum exposed to standard lactate-buffered PDF for 20 weeks (A, N = 11), standard lactate-buffered PDF for 12 weeks followed by
exposure to low-GDP bicarbonate/lactate-buffered PDF for 8 weeks (B, N = 10), and low-GDP bicarbonate/lactate-buffered PDF for 20 weeks
(C, N = 10).
TGF-b was up-regulated in the standard PDF group
compared with the bicarbonate/lactate PDF group. In-
termediary values were measured in the crossover group
(Table 1, Fig. 5). Fibrosis was more pronounced after 12
and 20 weeks exposure to standard PDF compared to bi-
carbonate/lactate PDF (Table 1, Fig. 6). The degree of
fibrosis in the crossover group did not differ significantly
from both the standard PDF and the bicarbonate/lactate
PDF treated groups (Table 1, Fig. 6). Fibrosis correlated
positively with TGF-b expression (Pearson r = 0.3129,
P < 0.05). Furthermore, AGE accumulation and VEGF
expression showed a positive correlation (Pearson r =
0.3229, P < 0.05).
DISCUSSION
Chronic exposure of the rat peritoneal membrane to
standard PDF is characterized by progressive fibrosis and
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Fig. 4. Advanced glycation end product (AGE) accumulation, expressed as percentage staining, was evaluated by an AGE immunostaining of the
visceral peritoneum exposed to standard lactate-buffered PDF for 20 weeks (A, N = 11), standard lactate-buffered PDF for 12 weeks followed by
exposure to low-GDP bicarbonate/lactate-buffered PDF for 8 weeks (B, N = 10), and low-GDP bicarbonate/lactate-buffered PDF for 20 weeks
(C, N = 10).
Fig. 5. TGF-b expression, expressed as percentage staining, was evaluated by a TGF-b immunostaining of the visceral peritoneum exposed
to standard lactate-buffered PDF for 20 weeks (A, N = 11), standard lactate-buffered PDF for 12 weeks followed by exposure to low-GDP
bicarbonate/lactate-buffered PDF for 8 week (B, N = 10), and low-GDP bicarbonate/lactate-buffered PDF for 20 weeks (C, N = 10).
neoangiogenesis associated with up-regulation of TGF-b
and VEGF, respectively. In addition, a pronounced AGE
accumulation was observed. Functionally, the membrane
is characterized by a loss of ultrafiltration capacity. Al-
though the present observations are descriptive and do
not prove causal relations, they support a key pathogenic
role for TGF-b and VEGF in the development of fibro-
sis and neoangiogenesis. The importance of these growth
factors has previously been demonstrated in animal mod-
els [13–16], but direct evidence in PD patients is presently
lacking. Furthermore, AGE accumulation is involved in
the development of peritoneal alterations, as their ca-
pacity to promote TGF-b expression through interaction
with RAGE has been evidenced [16], and they are known
to up-regulate VEGF [17, 18]. The peritoneal changes
tend to progress with time, confirming the results ob-
tained in cross-sectional and longitudinal studies in PD
patients [2, 3, 19].
Long-term treatment of the rat peritoneal membrane
with the low-GDP bicarbonate/lactate-buffered PDF in-
duced less neoangiogenesis with a concomitant lower
eNOS and VEGF expression, and was associated with
less AGE accumulation, TGF-b expression, and fibrosis
compared to standard PDF. In addition, ultrafiltration ca-
pacity was better preserved. These findings confirm previ-
ous observations in chronic rat models of peritoneal expo-
sure [7, 8]. Clinical studies found increased ultrafiltration
[10], elevated CA125, and decreased hyaluronan levels
[9] in patients treated with bicarbonate/lactate-buffered
PDF, suggestive of a better preservation of peritoneal
membrane homeostasis. Unfortunately, but for obvious
reasons, no direct comparisons of peritoneal membrane
morphology are available. In our previous work, peri-
toneal membrane function and structure was similar af-
ter 12 weeks exposure to bicarbonate/lactate PDF and
a buffer solution, suggesting that high glucose concen-
trations in the absence of other bioincompatible factors
were not harmful to the peritoneum at that point. How-
ever, the present results at 20 weeks of study demonstrate
that fibrosis and neoangiogenesis progress with time, also
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Fig. 6. Fibrosis was evaluated with a Picro Sirius Red staining of the visceral peritoneum exposed to standard lactate-buffered PDF for 20 weeks
(A, N = 11), standard lactate-buffered PDF for 12 weeks followed by exposure to low-GDP bicarbonate/lactate-buffered PDF for 8 weeks (B,
N = 10), and low-GDP bicarbonate/lactate-buffered PDF for 20 weeks (C, N = 10).
in the low-GDP bicarbonate/lactate-buffered treated an-
imals, suggesting that glucose by itself is capable of in-
ducing these changes. The present study thus indicates
that the PDF-induced changes are time-dependent, and
underlines the importance of sufficiently long exposure
periods in experimental animal models in order to reveal
long-term PDF-induced effects.
The salient observation of the present study, however,
is that crossover from the standard PDF to low-GDP
bicarbonate/lactate-buffered PDF was associated with
less peritoneal membrane deterioration than continu-
ous exposure to standard PDF. In PD patients, crossover
from a conventional PDF to a glucose-free regimen [20]
or low-GDP lactate-buffered PDF [21] was associated
with improvement of different markers of peritoneal in-
tegrity: CA125 levels increased, whereas hyaluronan lev-
els, local VEGF production, and circulating AGE levels
decreased. If the present observations are confirmed in
clinical trials, a switch to low-GDP bicarbonate/lactate-
buffered PDF may be an alternative to peritoneal resting
or transfer to hemodialysis for the management of pa-
tients with peritoneal membrane dysfunction.
CONCLUSION
The present study confirms the superior biocompati-
bility of the low-GDP bicarbonate/lactate-buffered PDF
during a long-term treatment period. Furthermore, this
new low-GDP, bicarbonate/lactate-buffered PDF with
physiologic pH has the potential to slow down peritoneal
damage induced by the standard PDF.
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